Gut microbiota alterations are associated with phenotype and genotype in familial Mediterranean fever

Rheumatology (Oxford). 2024 Apr 2;63(4):1039-1048. doi: 10.1093/rheumatology/kead322.

Abstract

Objective: FMF is the most common monogenic autoinflammatory disease associated with MEFV mutations. Disease phenotype and response to treatment vary from one patient to another, despite similar genotype, suggesting the role of environmental factors. The objective of this study was to analyse the gut microbiota of a large cohort of FMF patients in relation to disease characteristics.

Methods: The gut microbiotas of 119 FMF patients and 61 healthy controls were analysed using 16 s rRNA gene sequencing. Associations between bacterial taxa, clinical characteristics, and genotypes were evaluated using multivariable association with linear models (MaAslin2), adjusting on age, sex, genotype, presence of AA amyloidosis (n = 17), hepatopathy (n = 5), colchicine intake, colchicine resistance (n = 27), use of biotherapy (n = 10), CRP levels, and number of daily faeces. Bacterial network structures were also analysed.

Results: The gut microbiotas of FMF patients differ from those of controls in having increased pro-inflammatory bacteria, such as the Enterobacter, Klebsiella and Ruminococcus gnavus group. Disease characteristics and resistance to colchicine correlated with homozygous mutations and were associated with specific microbiota alteration. Colchicine treatment was associated with the expansion of anti-inflammatory taxa such as Faecalibacterium and Roseburia, while FMF severity was associated with expansion of the Ruminococcus gnavus group and Paracoccus. Colchicine-resistant patients exhibited an alteration of the bacterial network structure, with decreased intertaxa connectivity.

Conclusion: The gut microbiota of FMF patients correlates with disease characteristics and severity, with an increase in pro-inflammatory taxa in the most severe patients. This suggests a specific role for the gut microbiota in shaping FMF outcomes and response to treatment.

Keywords: FMF; colchicine; dysbiosis; gut microbiota.

MeSH terms

  • Clostridiales*
  • Colchicine / therapeutic use
  • Familial Mediterranean Fever* / complications
  • Familial Mediterranean Fever* / drug therapy
  • Familial Mediterranean Fever* / genetics
  • Gastrointestinal Microbiome* / genetics
  • Genotype
  • Humans
  • Mutation
  • Phenotype
  • Pyrin / genetics

Substances

  • Colchicine
  • Pyrin
  • MEFV protein, human

Supplementary concepts

  • Ruminococcus gnavus